Investments
794Portfolio Exits
221Funds
24Partners & Customers
3Expert Collections containing Atlas Venture
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Find Atlas Venture in 2 Expert Collections, including Synthetic Biology.
Synthetic Biology
382 items
CB Insights Healthcare Smart Money Investors - 2020
25 items
Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.
Latest Atlas Venture News
Apr 21, 2022
Sionna Therapeutics , a Boston, MA-based life sciences company developing differentiated treatments for cystic fibrosis (CF), closed a $111m Series B financing. The round was led by OrbiMed with participation from funds advised by T. Rowe Price Associates, Inc., Q Healthcare Holdings, LLC., a wholly owned subsidiary of QIA, the sovereign wealth fund of Qatar, and previous investors including RA Capital, TPG’s The Rise Fund, Atlas Venture, and the Cystic Fibrosis Foundation. The company, which has raised approximately $150m to date, intends to use the funds to advance development of a franchise of small molecules targeting NBD1 and complementary modulators, including NBD1’s interface with the intracellular loop 4 (ICL4) region and the transmembrane domain 1 (TMD1) of CFTR. Sionna plans to submit Investigational New Drug applications (IND) for its first NBD1 targeted program, SION-638, and for its lead ICL4 program, SION-109, within the next 12 months. Led by Mike Cloonan, President and Chief Executive Officer, Charlotte McKee, M.D., Chief Medical Officer, John Macor, Ph.D., Chief Scientific Officer, Elena Ridloff, Chief Financial Officer, Greg Hurlbut, Ph.D., Co-founder, Senior Vice President, Discovery Research, and Mark Munson, Ph.D., Co-founder, Vice President, Medicinal Chemistry, Sionna Therapeutics is a life sciences company dedicated to developing highly effective and differentiated treatments for cystic fibrosis (CF) by normalizing the function of CFTR, the key protein associated with disease progression in CF. The company is advancing a pipeline of first-in-class small molecules designed to fully restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein that is defective in CF, by stabilizing CFTR’s first nucleotide-binding domain (NBD1). The company’s Board of Directors includes: Josh Resnick, M.D., Chair, Managing Director, RA Capital Bruce Booth, D.Phil., Partner, Atlas Venture Mike Cloonan, President & CEO, Sionna Therapeutics Lucian Iancovici, M.D., Managing Director, TPG Life Sciences Innovation Adam Rosenberg, J.D., Venture Partner, RA Capital Peter Thompson, M.D., Partner, OrbiMed FinSMEs 21/04/2022
Atlas Venture Investments
794 Investments
Atlas Venture has made 794 investments. Their latest investment was in Sionna Therapeutics as part of their Series B on April 4, 2022.
Atlas Venture Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/19/2022 | Series B | Sionna Therapeutics | $111M | Yes | 4 | |
4/14/2022 | Series B | Be Biopharma | $130M | No | Alta Partners, ARCH Venture Partners, Bristol-Myers Squibb, Longwood Fund, RA Capital Management, Takeda Ventures, and Undisclosed Investors | 2 |
2/16/2022 | Series B | Third Harmonic Bio | $105M | No | 15 | |
2/10/2022 | Series B | |||||
1/5/2022 | Series B |
Date | 4/19/2022 | 4/14/2022 | 2/16/2022 | 2/10/2022 | 1/5/2022 |
---|---|---|---|---|---|
Round | Series B | Series B | Series B | Series B | Series B |
Company | Sionna Therapeutics | Be Biopharma | Third Harmonic Bio | ||
Amount | $111M | $130M | $105M | ||
New? | Yes | No | No | ||
Co-Investors | Alta Partners, ARCH Venture Partners, Bristol-Myers Squibb, Longwood Fund, RA Capital Management, Takeda Ventures, and Undisclosed Investors | ||||
Sources | 4 | 2 | 15 |
Atlas Venture Portfolio Exits
221 Portfolio Exits
Atlas Venture has 221 portfolio exits. Their latest portfolio exit was Vigil Neuroscience on January 07, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
1/7/2022 | IPO | 7 | |||
12/15/2021 | Acquired | 2 | |||
11/5/2021 | IPO | 6 | |||
Atlas Venture Acquisitions
2 Acquisitions
Atlas Venture acquired 2 companies. Their latest acquisition was NovusPharma on September 20, 1999.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
9/20/1999 | Convertible Note | Management Buyout | 1 | |||
5/27/1993 |
Date | 9/20/1999 | 5/27/1993 |
---|---|---|
Investment Stage | Convertible Note | |
Companies | ||
Valuation | ||
Total Funding | ||
Note | Management Buyout | |
Sources | 1 |
Atlas Venture Fund History
24 Fund Histories
Atlas Venture has 24 funds, including Atlas Venture Fund XIII.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
3/3/2022 | Atlas Venture Fund XIII | $450M | 1 | ||
7/6/2020 | Accomplice Fortuity Pool | $110M | 1 | ||
6/5/2020 | Atlas Venture Fund XII | $400M | 2 | ||
5/6/2020 | Pride Fund | ||||
1/2/2019 | Atlas Venture Opportunity Fund I |
Closing Date | 3/3/2022 | 7/6/2020 | 6/5/2020 | 5/6/2020 | 1/2/2019 |
---|---|---|---|---|---|
Fund | Atlas Venture Fund XIII | Accomplice Fortuity Pool | Atlas Venture Fund XII | Pride Fund | Atlas Venture Opportunity Fund I |
Fund Type | |||||
Status | |||||
Amount | $450M | $110M | $400M | ||
Sources | 1 | 1 | 2 |
Atlas Venture Partners & Customers
3 Partners and customers
Atlas Venture has 3 strategic partners and customers. Atlas Venture recently partnered with Caribou Biosciences on November 11, 2014.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
11/18/2014 | Partner | United States | Caribou Biosciences Announces Co-Founding of Intellia Therapeutics `` Caribou Biosciences is an ideal partner for Intellia Therapeutics as we seek to rapidly advance new therapies into the clinic , while further developing the technology to realize its full potential for a wide range of patient needs . '' | 1 | |
3/17/2014 | Partner | ||||
12/15/2011 | Partner |
Date | 11/18/2014 | 3/17/2014 | 12/15/2011 |
---|---|---|---|
Type | Partner | Partner | Partner |
Business Partner | |||
Country | United States | ||
News Snippet | Caribou Biosciences Announces Co-Founding of Intellia Therapeutics `` Caribou Biosciences is an ideal partner for Intellia Therapeutics as we seek to rapidly advance new therapies into the clinic , while further developing the technology to realize its full potential for a wide range of patient needs . '' | ||
Sources | 1 |
Atlas Venture Team
25 Team Members
Atlas Venture has 25 team members, including current Chief Financial Officer, Ommer Chohan.
Name | Work History | Title | Status |
---|---|---|---|
Ommer Chohan | Chief Financial Officer | Current | |
Michael Forkel | Controller | Current | |
Diana Mac | Controller | Current | |
David Grayzel | Managing Director | Current | |
Jodie Morrison | General Partner | Current |
Name | Ommer Chohan | Michael Forkel | Diana Mac | David Grayzel | Jodie Morrison |
---|---|---|---|---|---|
Work History | |||||
Title | Chief Financial Officer | Controller | Controller | Managing Director | General Partner |
Status | Current | Current | Current | Current | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.